Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from HUTCHMED (China) ( (HK:0013) ) is now available.
HUTCHMED has vested a total of 726,317 ordinary shares under its Long Term Incentive Plan following the release of its 2025 annual results, granting 524,079 shares to CEO and Chief Scientific Officer Dr Weiguo Su and 202,238 shares to Executive Director, Acting CEO and CFO Johnny Cheng. The nil‑cost vesting, conducted outside a trading venue, reinforces equity-based remuneration for top management and may be seen by investors as aligning leadership incentives with long-term shareholder value.
The company disclosed the transactions in line with UK Market Abuse Regulation requirements, highlighting its multi-listing governance obligations across Nasdaq, AIM and the Hong Kong Stock Exchange. By strengthening management’s equity stake as it advances its oncology and immunology portfolio globally, HUTCHMED signals continued commitment to executive retention and long-term strategic execution in a competitive biopharma landscape.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. Its first three medicines are marketed in China, with one also approved in major global markets including the US, Europe and Japan, underscoring its international oncology ambitions.
Learn more about 0013 stock on TipRanks’ Stock Analysis page.